DOCSLIB.ORG

Oxpentifylline and Cetiedil Citrate Improve Deformability of Dehydrated Sickle Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oxpentifylline and Cetiedil Citrate Improve Deformability of Dehydrated Sickle Cells J Clin Pathol: first published as 10.1136/jcp.40.10.1182 on 1 October 1987. Downloaded from J Clin Pathol 1987;40:1182-1186 Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells J STUART, P C W STONE, YY BILTO, A J KEIDAN From the Department ofHaematology, Medical School, University ofBirmingham, Birmingham SUMMARY Erythrocytes from 14 patients with homozygous sickle cell anaemia were treated with the calcium ionophore A23187 to induce loss of cellular potassium and water. The dehydrated cells showed a decrease in filterability (loss of deformability) through pores of 5 gm diameter. Ox- pentifylline and cetiedil citrate, which preserve erythrocyte cation and water content, had a significant (p < 0-01) protective effect against loss of deformability at a concentration of 1 gmol/l. Oxpentifylline showed no adverse effect on the rheology, morphology, or haemolysis of sickle cells at concentrations up to 500 jmol/l. Drugs that act on the erythrocyte membrane to maintain cell hydration are of potential rheological benefit in sickle cell anaemia. The dense erythrocytes in patients with sickle cell ana- 14 patients with homozygous (SS) sickle cell anaemia. emia are depleted of potassium' and the associated Oxpentifylline was compared, at equimolar concen- loss of cell water contributes to their high mean cell trations, with the iminoester cetiedil citrate which alsocopyright. haemoglobin concentration (MCHC).2 4 Increase in changes the cation content ofsickle cells by increasing MCHC greatly increases the intracellular poly- passive influx of sodium or preventing loss of potas- merisation of haemoglobin S (HbS)s so that polymer sium induced by calcium gain. 17 - 20 Intravenous may form at arterial oxygen tension.6 infusion of cetiedil has been shown to shorten the It is not known whether sickle cells lose potassium duration of vaso-occlusive crisis.2' and water by direct leakage through a cell membrane distorted by extended spicules of polymer,7 or by Material and methods opening the Gardos8 channel in response to transient http://jcp.bmj.com/ increases in cytoplasmic calcium before this cation be- The 14 SS patients were in the asymptomatic steady comes compartmentalised in membrane vesicles.9 Al- state. Heparinised venous blood was washed through ternatively, young sickle cells that swell in response to Imugard IG 500 cotton wool (Terumo Corporation, a fall in pH at sites of ischaemia may lose potassium Tokyo, Japan), using 20 mmol/l HEPES buffered sa- and water via the recently described volume sensitive line (HBS) of osmolality 290 mmol/Kg H20 and pH KCI cotransport system.'0" Whatever the cause of 7 4, to give a suspension of leucocyte free washed their dehydration, the deformability of sickle cells is erythrocytes.22 Passage through cotton wool does not on September 27, 2021 by guest. Protected adversely affected by the increase in MCHC122" and selectively remove irreversibly sickled cells23 or other is substantially improved by rehydration.12 14 dense sickle cells,24 and HBS has been shown not to Oxpentifylline is a dimethyl xanthine derivative change the MCHC of sickle cells.25 that binds reversibly to erythrocyte membranes Filtration of oxygenated sickle cells through poly- and has been shown to increase walking distance in carbonate membranes with pores of 5 g.m diameter patients with atherosclerotic intermittent claudica- and 10-I Ilm length (Nuclepore Corporation, Pleas- tion.'5 We have recently shown that the drug pre- anton, California, USA) was measured at 37°C using vents loss of potassium and therefore water from a Hemorheometre (IMH, 95470 St Witz, France) to normal (haemoglobin AA) erythrocytes that had been give an index of filtration (IF) corrected for erythro- loaded with calcium using the ionophore A23187.16 cyte count.'6 This index is the ratio of the flow re- The same experimental model has now been used to sistance of erythrocytes suspended in HBS at a cell study the action of oxpentifylline on sickle cells from count of 0 3 x 1012/I to that of HBS alone, and is expressed as relative resistance rather than absolute Accepted for publication 21 December 1987 units; an increase in IF indicates loss of erythrocyte 1182 J Clin Pathol: first published as 10.1136/jcp.40.10.1182 on 1 October 1987. Downloaded from Improving the deformability ofdehydrated sickle cells 1183 (841) 100 80 560- 60- 480- & 40- c ;2020- 6400° so I .3- 0 320 0< w K 0- 1-- .3 ST 0 240- ;-40 -a a" * - : -60- -3 160 01~ . - -80 -100 1 10 100 500 1 lb 160 5so 0- Oxpentifylline (prnol/l) Cetiedil (pmol/I) Buffer A 23187 Fig 2 Index offiltration ofsickle cells after incubation for Fig I Index ojfiltration (IF) ofsickle cells from 14 60 minutes in buffer containing A23187 ionophore and either patients after incubation ofcells for 60 minutes in control oxpentifylline or cetiedil citrate. Results (mean and 95% buffer and in buffer with calcium ionophore A23187. confidence intervalfor 14 patients) expressed as percentage copyright. Increase in IF indicates loss offilterability. change from IF valuesfor sickle cells incubated wilh A23187 (fig 1) but without either drug. deformability. A pore diameter of 5 gm rather than 3 sessed by interference microscopy on 300 oxygenated gm was used as this enhances sensitivity to cyto- cells fixed with 125% w/v glutaraldehyde in HBS, plasmic viscosity and therefore to cytoplasmic hy- using the Bessis classification29 for stomatocytes and dration.2627 The polycarbonate membranes were echinocytes. Cells whose length was twice their width cleaned by ultrasonication in 1% w/v sodium dodecyl or those which had angular contours were counted as http://jcp.bmj.com/ sulphate and reused.28 irreversibly sickled cells (ISC).30 The extent of hae- A stock solution of the calcium ionophore A23 187 molysis of the erythrocyte suspensions was assessed (Calbiochcm brand, Behring Diagnostics, La Jolla, from the supernatant haemoglobin concentration, California, USA) in absolute ethanol ([-9 mmol/l) measured spectrophotometrically using tetramethyl was stored at -40°C and diluted in ice cold HBS benzidine. Significance (two tail) was determined by immediately before use. Oxygenated sickle cells Wilcoxon's non-parametric signed rank test for (0-3 x 1012/I) were incubated for 60 minutes at 37°C paired data. on September 27, 2021 by guest. Protected in control buffer (HBS, CaCI2 100 jmol/l, MgCl2 2 mmol/l, glucose 10 mmol/l) and in control buffer plus Results A23187. As there was considerable individual vari- ation in response to ionophore a concentration of Calcium loading of sickle cells using A23187 iono- A23 187 (range 0 5--13 pmol/l) which increased the IF phore caused an increase in IF (loss of filterability) value by at lcast two-fold, was selected for each pa- after 60 minutes compared with cells in control buffer tient. Oxpentifylline or cetiedil citrate, at final drug (fig 1). As there was considerable variation between concentrations of 0, 1, 10, 100 and 500 gmol, was patients in the extent to which A23187 increased IF, added to the cell suspensions at 37°C, 15 minutes be- the effects of oxpentifylline and cetiedil citrate were fore the addition of ionophore. Oxpentifylline was expressed as pcrcentage change from the IF value af- dissolved in HBS immediately before use. A stock ter incubation with A23 187 alone (fig 2). All four con- solution of cetiedil citrate in absolute ethanol (125 centrations of oxpentifylline significantly improved mmol/l) was stored at -40°C. IF (10 pmol/l, p < 0-05; other concentrations, Morphology of incubated erythrocytes was as- p <0 01) and caused no change in erythrocyte mor- J Clin Pathol: first published as 10.1136/jcp.40.10.1182 on 1 October 1987. Downloaded from 1184 Stuart, Stone, Bilto, Keidan Table Effect ofoxpentifylline and cetiedil on erythrocyte of small amounts of intracellular polymer in sickle morphology and haemolysis after incubation with A23187 erythrocytes at arterial oxygen tension.34 ionophore for 60 minutes (mean and SEM, n = 14) Cetiedil is a vasodilator" that enhances passive en- Irreversibly Supernatant try of sodium into erythrocytes17 18 and decreases po- Stomatocytes Echinocytes sickled cells haemoglobin tassium loss via the Gardos pathway after calcium (%) (%) (%) (mg/I) loading.19 20 Both mechanisms could increase cell Control buffer 49 8-1 9.7 97 water, reduce MCHC and cytoplasmic viscosity, and (1 9) (1.4) (2-1) (7) thus improve erythrocyte deformability. Intravenous A23187 35 19l1t 83 101 cetiedil (0-4 mg/kg body weight) has been shown to (1-2) (4-9) (2-2) (4) Oxpentifylline: shorten the duration of vaso-occlusive crisis,21 and a 1 ,mol/1 3-7 17-4 9-3 107 single infusion at this dose gives a peak plasma con- (1-0) (3-0) (2 5) (8) 10 jmol/I 4-2 16-3 8-6 114 centration of 025 jsmol/l.36 A previous in vitro (1 1) (4-1) (2-0) (7) filtration study of deoxygenated sickle cells showed a 100 1mol/I 5-3 11-4 9.3 99 (1.7) (2-9) (2-0) (3) beneficial effect of cetiedil at 50-200 jmol/l, with no 500 jmol/I 4 5 13.0 8-4 94 effect on oxygenated cells.37 The higher sensitivity of (2-9) (2 8) (2-0) (5) our filtration technique detected an effect on oxygen- Cetiedil: I Sumol/1 59 13-1 8-9 97 ated SS cells treated with ionophore at I pmol/l, the (2-1) (2-9) (2 0) (5) lowest concentration studied. At 100 jimol/l and 10lmol/l 8-4* 8-1* 8-2 110 (2-0) (1-8) (1-8) (6) above, the drug caused substantial cell swelling (sto- 100 imol/I 70-1* 2.1* 5-0 1537* matoxytosis) and haemolysis, as previously re- (4 9) (0 8) (0 9) (684) 500 mol/l 99-1* 0* 0-8* 11316* ported.17 18 (0-3) (0-3) (104) Oxpentifylline has recently been shown to reduce loss of potassium and therefore water from normal tp < 0 01 compared with buffer value.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • 勃起不能治療準則 賴依伶 毛箴言 林口長庚紀念醫院藥劑科 台北藥劑組 本稿譯自 European Association of Urology：GUIDELINES on ERECTILE DYSFUNCTION
    發行人：張文棟 總 編：鄧新棠 主 編：李炳鈺 發行所：林口、高雄、台北、基隆、 嘉義。長庚紀念醫院藥劑學部 一○一年三月十五日出版 勃起不能治療準則 賴依伶 毛箴言 林口長庚紀念醫院藥劑科 台北藥劑組 本稿譯自 European Association of Urology：GUIDELINES ON ERECTILE DYSFUNCTION. Uptodate 2005 Mar. 背景 知識而來；事實上，有愈來愈多資料顯示 ED 和心 1.1 介紹 血管疾病有許多共同的風險因素：缺少運動、過 新型口服療法已經完全改變診斷與治療勃起 胖、抽煙、高血脂和新陳代謝不良，其他與生活方 不能(erectile dysfunction以下簡稱ED)的方法。為 式相關的風險因素是可以改善的。在 MMAS 研究 了更新先前為臨床評估和治療所建立的指導方 中，與中年仍慣於久坐的男性相較之下，中年從事 針，「EAU指導處」已經集合相關領域的專家，成 體能活動男性發生 ED 的風險降低了 70%；同一份 立了專案小組。 研究的長期結果顯示，在八年的追蹤期間，定期運 修正的依據是重新審視現有的科學資訊，以及 動的 ED 發生率明顯降低許多。一份由許多機構共 相關領域中的現行研究和臨床診療。此外，專案小 同參與的隨機化開放標籤研究中，比較兩年下來密 組已經指出數項重大問題和知識差距，並設定未來 集運動和適當減重的過胖 ED 男性。觀察到在改變 臨床研究的先後順序。 生活方式的小組中，BMI 指數、身體活動度和勃起 1.2 流行病理與風險因素 功能都顯著改善，而這些改變也和體重減輕與活動 男性勃起障礙向來被定義為無法達到且持續 的程度密切相關。然而需要強調的是，需要有更多 勃起，導致性行為表現不足以帶來滿足。雖然 ED 研究以研判運動或其他改變生活方式對預防或治 不是惡性的異常，但卻與生理和心理健康有關，而 療 ED 的效果。 且嚴重影響患者與其伴侶、家庭的生活品質。 1.3 管理 ED: 日常臨床診療的建議 近來的流行病理資料顯示，世界各地都有日趨 在過去 15 年來，針對 ED 的基礎和臨床研究 嚴重的 ED 問題。首次大規模的社區型研究「麻州 已經發展出數種新式療法，包括對海綿體、尿道內 男性老化研究」(MMAS)指出，在波士頓地區，40 和近來的口服藥劑。在長期追蹤中，血管重建手術 到 70 歲之機構外男性中，52%有 ED 的情形。在 與成效不彰有關。因此，治療策略已經過大幅修正。 這份研究中，輕微、中度和完全 ED 的比例分別為 目前已經有有效且安全的 ED 口服藥物，加上 17.2%、25.2%和 9.6%。在「科倫研究」中(30-80 媒體對此題材的興趣濃厚，導致有愈來愈多男性尋 歲男性)，ED 的比例是 19.2%,，隨著年齡增加而急 求改善 ED。許多醫師即使缺乏 ED 的專業背景知 速升高(2.3%~53.4%)。另一方面，「國家健康與社 識和臨床診療 ED 的經驗，也相繼參與決定針對這 會生活調查」則指出有 31%的性功能障礙(不單指 些男性病例的評估和治療。因此有些 ED 的男性在 ED)。MMAS 研究中的長期分析估計，每年每一千 開始接受治療之前，可能都未經過適當評估或完全 名男性中就會多出 26 個新案例。而在一份巴西與 沒有評估；或是沒有 ED 的男性也可能為了增強性 另一份荷蘭的研究中，則估計 ED 發生率（每年每 行為表現，而尋求治療。在這些因素下，真正導致 一千名男性中的新案例）分別為千分之 65.6(追蹤 ED 的基本疾病可能始終都未經治療。這樣的觀察 二年)和千分之 19.2(追蹤 4.2 年)。這些研究的差 結果顯示，發展診斷和治療
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn Et Al
    US 2003.0068365A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0068365A1 Suvanprakorn et al. (43) Pub. Date: Apr. 10, 2003 (54) COMPOSITIONS AND METHODS FOR Related U.S. Application Data ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME BEADS (60) Provisional application No. 60/327,643, filed on Oct. 5, 2001. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); Tanusin Ploysangam, Bangkok (TH); Publication Classification Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok (51) Int. Cl." .......................... A61K 9/127; A61K 35/78 (TH); Nardo Zaias, Miami Beach, FL (52) U.S. Cl. ............................................ 424/450; 424/725 (US) (57) ABSTRACT Correspondence Address: Law Office of Eric G. Masamori Compositions and methods for administration of active 6520 Ridgewood Drive agents encapsulated within liposome beads to enable a wider Castro Valley, CA 94.552 (US) range of delivery vehicles, to provide longer product shelf life, to allow multiple active agents within the composition, (21) Appl. No.: 10/264,205 to allow the controlled use of the active agents, to provide protected and designable release features and to provide (22) Filed: Oct. 3, 2002 Visual inspection for damage and inconsistency. US 2003/0068365A1 Apr. 10, 2003 COMPOSITIONS AND METHODS FOR toxic degradation of the products, leakage of the drug from ADMINISTRATION OF ACTIVE AGENTS USING the liposome and the modifications of the Size and morphol LPOSOME BEADS ogy of the phospholipid liposome vesicles through aggre gation and fusion. Liposome vesicles are known to be CROSS REFERENCE TO OTHER thermodynamically relatively unstable at room temperature APPLICATIONS and can Spontaneously fuse into larger, leSS Stable altered liposome forms.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • 2021 Equine Prohibited Substances List
    2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s). Prohibited Substances that are identified as Specified Substances in the List below should not in any way be considered less important or less dangerous than other Prohibited Substances. Rather, they are simply substances which are more likely to have been ingested by Horses for a purpose other than the enhancement of sport performance, for example, through a contaminated food substance. LISTED AS SUBSTANCE ACTIVITY BANNED 1-androsterone Anabolic BANNED 3β-Hydroxy-5α-androstan-17-one Anabolic BANNED 4-chlorometatandienone Anabolic BANNED 5α-Androst-2-ene-17one Anabolic BANNED 5α-Androstane-3α, 17α-diol Anabolic BANNED 5α-Androstane-3α, 17β-diol Anabolic BANNED 5α-Androstane-3β, 17α-diol Anabolic BANNED 5α-Androstane-3β, 17β-diol Anabolic BANNED 5β-Androstane-3α, 17β-diol Anabolic BANNED 7α-Hydroxy-DHEA Anabolic BANNED 7β-Hydroxy-DHEA Anabolic BANNED 7-Keto-DHEA Anabolic CONTROLLED 17-Alpha-Hydroxy Progesterone Hormone FEMALES BANNED 17-Alpha-Hydroxy Progesterone Anabolic MALES BANNED 19-Norandrosterone Anabolic BANNED 19-Noretiocholanolone Anabolic BANNED 20-Hydroxyecdysone Anabolic BANNED Δ1-Testosterone Anabolic BANNED Acebutolol Beta blocker BANNED Acefylline Bronchodilator BANNED Acemetacin Non-steroidal anti-inflammatory drug BANNED Acenocoumarol Anticoagulant CONTROLLED Acepromazine Sedative BANNED Acetanilid Analgesic/antipyretic CONTROLLED Acetazolamide Carbonic Anhydrase Inhibitor BANNED Acetohexamide Pancreatic stimulant CONTROLLED Acetominophen (Paracetamol) Analgesic BANNED Acetophenazine Antipsychotic BANNED Acetophenetidin (Phenacetin) Analgesic BANNED Acetylmorphine Narcotic BANNED Adinazolam Anxiolytic BANNED Adiphenine Antispasmodic BANNED Adrafinil Stimulant 1 December 2020, Lausanne, Switzerland 2021 Equine Prohibited Substances List . Prohibited Substances include any other substance with a similar chemical structure or similar biological effect(s).
    [Show full text]
  • Wo 2007/120485 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 25 October 2007 (25.10.2007) WO 2007/120485 A2 (51) International Patent Classification: IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, A61K 31/195 (2006.01) LS, LT, LU, LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, (21) International Application Number: RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, PCT/US2007/0081 14 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 30 March 2007 (30.03.2007) (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (26) Publication Language: English European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, (30) Priority Data: 60/787,150 30 March 2006 (30.03.2006) US GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (71) Applicant (for all designated States except US): CINER- — as to applicant's entitlement to apply for and be granted a GEN, LLC [US/US]; 146 Medinah Drive, Blue Bell, PA patent (Rule 4.17(U)) 19422-3212 (US).
    [Show full text]
  • Medical Product Quality Report – COVID-19 Issues
    Medical Product Quality Report – COVID-19 Issues Issue 7. December 2020 The document has been produced by the Medicine Quality Research Group, Centre of Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford 1 This report was prepared by Kerlijn Van Assche, Céline Caillet and Paul Newton of the Medicine Quality Research Group, that is part of the Infectious Diseases Data Observatory (IDDO) and the MORU Tropical Health Network, Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, UK. The Globe system was developed by Clark Freifeld (HealthMap, Boston Children’s Hospital, North Eastern University) and Andrew Payne (IDDO), Alberto Olliaro (IDDO) and Gareth Blower (ex-IDDO) with curation of the English reports by Konnie Bellingham, Kitignavong Inthaphavanh and Vayouly Vidhamaly, linked to the Lao-Oxford-Mahosot Hospital- Wellcome Trust Research Unit (LOMWRU), Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao PDR. This document is open access but we would be grateful if you could cite it as: Medicine Quality Research Group, University of Oxford. Medical Product Quality Report – COVID-19 Issues. Issue 7, December 2020. The work is kindly supported by the Bill&Melinda Gates Foundation, the University of Oxford and the Wellcome Trust. January 2020 2 Contents 1. Summary of findings ..................................................................................................... 4 2. Introduction ..................................................................................................................
    [Show full text]